JP5226912B2 - Ppar活性化剤 - Google Patents
Ppar活性化剤 Download PDFInfo
- Publication number
- JP5226912B2 JP5226912B2 JP2000174803A JP2000174803A JP5226912B2 JP 5226912 B2 JP5226912 B2 JP 5226912B2 JP 2000174803 A JP2000174803 A JP 2000174803A JP 2000174803 A JP2000174803 A JP 2000174803A JP 5226912 B2 JP5226912 B2 JP 5226912B2
- Authority
- JP
- Japan
- Prior art keywords
- ppar
- monoacylglycerol
- fatty acid
- acid
- activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Description
本発明の目的は長期間摂取しても安全性に優れ、高い効力を有するPPAR活性化剤を提供することにある。
小腸上皮細胞株IEC−6または肝細胞株HepG2を12well plateにまき、DMEM(5%FCS)中で1日培養する。PPAR応答配列(下線)(AACgTgACCTTTgTCCTggTCAACgTgACCTTTgTCCTggTC AACgTgACCTTTgTCCTggTC)を含むDNA鎖、SV40プロモター遺伝子、蛍ルシフェラーゼ遺伝子を含むPPARレポータープラスミド(PPAR-Luc)及び、ウミシイタケルシフェラーゼ遺伝子の上流にチミジンキナーゼプロモーター遺伝子を連結したコントロールプラスミド(TK-Luc:Promega)を同時に各々0.5μg/wellとなるようトランスフェクション試薬(Superfect transfection reagent;QIAGEN)を用いて導入した。その後培養液を被験物質を含むDMEM(-FCS、+250μM BSA)培地に交換し、さらに24時間培養した。PBSにて洗浄後デュアルルシフェラーゼアッセイシステム(Promega)を用いて細胞を溶解、溶解液にルシフェリンを含む基質溶液を加え、ルミノメーターにて蛍及びウミシイタケルシフェラーゼ活性を各々測定した。本実験系でPPAR依存的な遺伝子の転写活性(ルシフェラーゼ活性)を測定することにより、PPAR活性化物質の探索を行った。尚、PPAR依存的な遺伝子の転写活性(ルシフェラーゼ活性)は以下のように定義した。
1−モノリノレニルグリセロール10g、ヒドロキシプロピルセルロース8g、軟質無水ケイ酸2g、乳糖5g、結晶セルロース5g、タルク5g及びジオレオイルグリセロール3gを混合し、直径9mm、重量200mgの錠剤を製造した。
1−モノオレオイルグリセロール20g、1−モノエイコサペンタエノイルグリセロール20g及びビタミンC2gを混合した後、ゼラチンカプセルに充填し、1錠250mgの軟ゼラチンカプセル剤を製造した。
1−モノリノレニルグリセロール20g、γ−オリザノール10g、無水カフェイン10g、ドコサヘキサエン酸10g、エイコサペンタエン酸10g、α−リノレン酸10g及びビタミンCを混合した後、ゼラチンカプセルに充填し、1錠250mgの軟ゼラチンカプセル剤を製造した。
Claims (2)
- 構成脂肪酸がオレイン酸又はリノール酸であるモノアシルグリセロールを有効成分とするペルオキシソーム増殖剤活性化受容体活性化剤。
- 構成脂肪酸がn−3系脂肪酸であるモノアシルグリセロール(但し、分子内に共役トリエン構造又は共役テトラエン構造を有する炭素数10〜26の共役不飽和脂肪酸のモノグリセリドを除く)を有効成分とするペルオキシソーム増殖剤活性化受容体活性化剤(但し、血糖値低下剤、インスリン抵抗改善剤又は血中インスリン濃度低下剤として使用する場合を除く)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000174803A JP5226912B2 (ja) | 2000-06-12 | 2000-06-12 | Ppar活性化剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000174803A JP5226912B2 (ja) | 2000-06-12 | 2000-06-12 | Ppar活性化剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001354558A JP2001354558A (ja) | 2001-12-25 |
JP2001354558A5 JP2001354558A5 (ja) | 2008-02-28 |
JP5226912B2 true JP5226912B2 (ja) | 2013-07-03 |
Family
ID=18676772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000174803A Expired - Fee Related JP5226912B2 (ja) | 2000-06-12 | 2000-06-12 | Ppar活性化剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5226912B2 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2002102364A1 (ja) * | 2001-06-18 | 2004-09-30 | 山田 幸子 | PPARγ作動性医薬組成物 |
KR100993113B1 (ko) | 2002-02-14 | 2010-11-08 | 기린 홀딩스 가부시키가이샤 | 지질대사 개선용 조성물 및 식품 |
FR2850869B1 (fr) * | 2003-02-12 | 2005-03-25 | Genfit S A | Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures |
DE10314078A1 (de) | 2003-03-28 | 2004-10-14 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Verfahren zur Aufreinigung von Verbindungen mit funktionellen Gruppen |
JP4634065B2 (ja) * | 2004-05-14 | 2011-02-16 | 花王株式会社 | アディポネクチン低下抑制剤 |
JP4972336B2 (ja) * | 2006-04-24 | 2012-07-11 | 花王株式会社 | Gip分泌抑制剤 |
JP4878494B2 (ja) * | 2006-04-24 | 2012-02-15 | 花王株式会社 | 食後血中インスリン上昇抑制剤 |
JP5798281B2 (ja) * | 2006-09-27 | 2015-10-21 | 株式会社セラバリューズ | PPARγ活性化剤 |
WO2008084864A1 (ja) * | 2007-01-11 | 2008-07-17 | Nisshin Pharma Inc. | カプサイシン受容体活性化剤及びそれを噴霧する装置 |
JP5385572B2 (ja) * | 2007-09-28 | 2014-01-08 | 出光興産株式会社 | Ppar結合作用剤 |
WO2010149170A1 (en) * | 2009-06-24 | 2010-12-29 | Københavns Universitet | Treatment of insulin resistance and obesity by stimulating glp-1 release |
JP2010241832A (ja) * | 2010-07-20 | 2010-10-28 | Kao Corp | アディポネクチン低下抑制剤 |
JP2012171911A (ja) | 2011-02-22 | 2012-09-10 | Kao Corp | Ppar活性化剤 |
JP2012171924A (ja) * | 2011-02-22 | 2012-09-10 | Kao Corp | Ppar活性化剤 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL64542A0 (en) | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
JP3098560B2 (ja) * | 1991-03-28 | 2000-10-16 | 花王株式会社 | 体重増加抑制剤 |
JP3098561B2 (ja) * | 1991-03-28 | 2000-10-16 | 花王株式会社 | 血清トリグリセリド濃度低下剤 |
JP2969234B2 (ja) * | 1991-07-19 | 1999-11-02 | 株式会社アドバンス | Acat阻害剤 |
JPH05310567A (ja) * | 1992-05-07 | 1993-11-22 | Kao Corp | 血清トリグリセリド濃度低下剤 |
EP1010432A4 (en) | 1997-01-23 | 2004-03-10 | Sumitomo Pharma | REMEDIES FOR DIABETES |
JP3607062B2 (ja) * | 1997-10-24 | 2005-01-05 | 株式会社コーセー | 脂肪蓄積抑制剤及びそれを含有する皮膚外用剤 |
AU1911999A (en) * | 1997-12-12 | 1999-06-28 | Penn State Research Foundation, The | Methods and compositions for treating diabetes |
JP2000355538A (ja) * | 1999-04-15 | 2000-12-26 | Kanegafuchi Chem Ind Co Ltd | ペルオキシゾーム活性化剤応答性受容体アゴニスト |
JP2001247473A (ja) * | 2000-03-06 | 2001-09-11 | Kao Corp | インスリン抵抗性改善剤 |
JP4139544B2 (ja) * | 2000-03-06 | 2008-08-27 | 花王株式会社 | 血糖値低下剤 |
-
2000
- 2000-06-12 JP JP2000174803A patent/JP5226912B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2001354558A (ja) | 2001-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Drouin et al. | The n-3 docosapentaenoic acid (DPA): A new player in the n-3 long chain polyunsaturated fatty acid family | |
Innes et al. | Omega-6 fatty acids and inflammation | |
Chapkin et al. | Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation | |
Khan et al. | Reviews: current topicsrole of nuclear receptors in the regulation of gene expression by dietary fatty acids | |
Nakamura et al. | Structure, function, and dietary regulation of Δ6, Δ5, and Δ9 desaturases | |
Liu et al. | Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease | |
Bocos et al. | Fatty acid activation of peroxisome proliferator-activated receptor (PPAR) | |
Schmitz et al. | The opposing effects of n− 3 and n− 6 fatty acids | |
JP5226912B2 (ja) | Ppar活性化剤 | |
Uauy et al. | Essential fatty acids in early life: structural and functional role | |
Calder et al. | Understanding omega-3 polyunsaturated fatty acids | |
Teitelbaum et al. | the role of omega 3 fatty acids in intestinal inflammation | |
Haggarty | Fatty acid supply to the human fetus | |
Wang et al. | The role of ruminant trans fat as a potential nutraceutical in the prevention of cardiovascular disease | |
Marszalek et al. | Docosahexaenoic acid, fatty acid–interacting proteins, and neuronal function: breastmilk and fish are good for you | |
Das | Essential fatty acids: biochemistry, physiology and pathology | |
JP5511126B2 (ja) | 脂質改善剤及び脂質改善剤を含んでなる組成物 | |
Riecan et al. | Branched and linear fatty acid esters of hydroxy fatty acids (FAHFA) relevant to human health | |
Calder | Nutritional benefits of omega-3 fatty acids | |
Tsuzuki et al. | Conjugated docosahexaenoic acid inhibits lipid accumulation in rats | |
Chapkin | Reappraisal of the essential fatty acids | |
Wang et al. | Reviews of medium-and long-chain triglyceride with respect to nutritional benefits and digestion and absorption behavior | |
Drenjančević et al. | The effect of dietary intake of Omega-3 polyunsaturated fatty acids on cardiovascular health: revealing potentials of functional food | |
Calder | Health benefits of omega-3 fatty acids | |
US20190000795A1 (en) | Methods of using cannabinoids and/or molecular similars for modulating, waking-up and/or disabling cellular functions involved in causing disease -- reinvigorating metabolism with anandamide, 2-arachidonoylglycerol and similarly acting compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060803 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20060803 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100126 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100329 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100511 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130212 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130315 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 5226912 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160322 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |